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The human genome is far smaller than originally estimated, and one explanation is that alternative splicing
creates greater proteomic complexity than a simple count of open reading frames would suggest. The p53
homologue p63, for example, is a tetrameric transcription factor implicated in epithelial development and
expressed as at least six isoforms with widely differing transactivation potential. In particular, p63 isoforms
contain a 27-kDa C-terminal region that drastically reduces their activity and is of clear biological importance,
since patients with deletions in this C terminus have phenotypes very similar to patients with mutations in the
DNA-binding domain. We have identified a novel domain within this C terminus that is necessary and sufficient
for transcriptional inhibition and which acts by binding to a region in the N-terminal transactivation domain
of p63 homologous to the MDM2 binding site in p53. Based on this mechanism, we provide a model that
explains the transactivation potential of homo- and heterotetramers composed of different p63 isoforms and
their effect on p53.
The recent discovery of two homologues of the archetypal
tumor suppressor protein p53, called p73 and p63 (p51/p40/
p73L/ket) (1, 35, 39, 46, 49), has sparked speculations that
surveillance of cellular integrity might be achieved through a
network of these p53-like tumor suppressors (10). These spec-
ulations were further fueled by the observation that the p73
gene is localized to chromosome 1p36.3, a region that is fre-
quently lost in neuroblastomas and other types of cancers (20,
43) while the p63 chromosomal location, 3q27-9, is deleted in
some bladder cancers and amplified in some cervical, ovarian,
lung, and squamous cell carcinomas (13, 49). Moreover, both
p73 and p63 can bind to p53 DNA-binding sites in vitro and
activate proteins under the control of a p53 promoter and
induce apoptosis in vivo (18, 49).
Despite all this circumstantial evidence, however, only a very
few mutations in p63 and p73 have been found in human
tumors, and a direct link to carcinogenesis similar to that for
p53 has so far not been established (17, 22, 27, 32, 43). Fur-
thermore, knockout mouse studies of both proteins have re-
vealed that they are involved in different biological processes.
p73-knockout mice are characterized by chronic infections and
developmental defects, including hippocampal dysgenesis, hy-
drocephalus, and abnormalities in the pheromone sensory
pathway (51). p63-knockout mice show even more severe de-
fects that include truncated limbs and a lack of all squamous
epithelia (29, 50). Both phenotypes are very unlike that of the
p53-knockout mice, which are without developmental defects
but have an elevated susceptibility to tumorigenesis (9). These
striking differences in biological function are surprising in light
of the high homology among all three proteins that reaches
65% identity in the DNA-binding domain, with all amino acids
that contact DNA being conserved. Most likely then, these
different biological functions are connected to domains outside
the DNA-binding domain unique to p73 and p63. Indeed, both
proteins exist in multiple isoforms. In the case of p63, at least
six different isotypes with widely differing transactivation po-
tentials have been described elsewhere (49). Three of these
isoforms are inactive due to the absence of the N-terminal
transactivation (TA) domain (N isoforms). The activity of the
remaining isoforms (TA isoforms) is modulated by three C-
terminal sequences, , , and , not found in p53. The smaller
p63 and p63 isoforms are transcriptionally active while the
presence of the 27-kDa  C-terminal domain drastically re-
duces the activity of p63 (49). In addition, Np63, which is
the major isoform found in cells, shows strong dominant-neg-
ative behavior toward transactivating p63 isoforms and mod-
erate dominant-negative behavior toward p53. The overarch-
ing importance of the  C-terminal domain to the biological
function of p63 is further emphasized by clinical observations.
A human patient with a mutation that introduces a premature
stop codon in the  C terminus shows skeletal reduction de-
fects of the hands and feet, surprisingly similar to patients with
a mutation in the DNA-binding domain (4). That this mutation
in the  C terminus affects only the two  isoforms (TAp63
and Np63) and yet produces very similar abnormalities as
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do mutations that eliminate DNA binding of all six p63 iso-
forms suggests that  isoforms play a pivotal role in p63 pro-
cesses.
We have identified an inhibitory domain within the  C
terminus that is both necessary and sufficient for transcrip-
tional inhibition. In this paper we demonstrate that this do-
main uses a new mode of inhibition by binding to a region in
the N-terminal TA domain of p63 that is homologous to the
MDM2 binding site in p53, masking residues that are impor-
tant for transactivation. Based on this intramolecular inhibi-
tion, we provide a model that makes sense of many past ex-
periments and explains how alternative splicing modulates the
transactivation potential of homo- and heterotetramers com-
posed of different p63 isoforms and how they regulate p53.
Given the high homology between the  C termini of p63 and
p73, the results presented here are also very likely relevant for
p73.
MATERIALS AND METHODS
Cell culture and transactivation assays. SAOS-2 cells were obtained from the
American Type Culture Collection. Cells were maintained in Dulbecco modified
Eagle medium with 10% fetal bovine serum at 37°C in a 5% CO2 atmosphere.
Transactivation assays were carried out with the dual-luciferase reporter assay
system (Promega) in SAOS-2 cells with 13 tandem repeats of an optimized
p53-binding sequence (from Bert Vogelstein) subcloned into a firefly luciferase
reporter vector (49). All experimental results were normalized for transfection
efficiency and sample preparation variations with a pRL-CMV control Renilla
luciferase plasmid (Promega). Experiments were performed in triplicate.
Expression vectors. For the transactivation cell culture assays all p63 and p53
constructs and mutants were cloned into a pcDNA3 vector (Invitrogen) as
XhoI-XbaI fragments and containing an N-terminal myc tag. Point mutants were
made with a QuikChange (Stratagene) mutagenesis kit. Glutathione S-trans-
ferase (GST) fusion vectors were constructed by inserting BamHI-EcoRI frag-
ments into a pGEX-6P-2 vector (Pharmacia Biotech). For the expression of the
TID25 peptide, the construct was cloned into a pET-31b() vector (Novagen)
as a single AlwNI fragment according to the kit instructions.
Immunoblotting. Transfected cell lysates were resolved on a sodium dodecyl
sulfate (SDS)–4 to 12% polyacrylamide gel electrophoresis (PAGE) gradient gel
(NuPAGE Bis-Tris; Invitrogen) and transferred to a polyvinylidene difluoride
(PVDF) membrane (Immobilon-P; Millipore). p63 isoforms, mutants, and chi-
meras were detected with the 4A4 monoclonal p63 antibody and/or the 9E10
c-Myc antibody. Secondary anti-mouse immunoglobulin G antibodies, conju-
gated to horseradish peroxidase (Santa Cruz Biotechnology), were applied, fol-
lowed by treatment with enhanced chemiluminescence (ECL) reagent (Amer-
sham Biosciences) and exposure to Kodak Biomax ML film.
Immunofluorescence. Transfection and immunofluorescence experiments
were carried out with BHK cells attached to 18-mm-diameter round glass cov-
erslips as described earlier (49). The 9E10 c-Myc-specific antibody was used as
the primary antibody against the N-terminally myc-tagged TAp63, followed by
staining with a Cy3-conjugated goat anti-mouse secondary antibody. DNA was
stained with the fluorochrome Hoechst 33278 (Sigma). myc-tagged TAp63 was
stained with the c-Myc-specific antibody 9E10.
Peptide expression and purification. The TID25 (residues 568 to 616) pep-
tide was expressed as a fusion to ketosteroid isomerase and a His tag, separated
from each by a methionine. The fusion was purified from inclusion bodies in a
denaturing buffer (6 M guanidine-HCl, 0.5 M NaCl, 5 mM imidazole, and 20 mM
Tris-HCl, pH 7.9) by Ni-affinity chromatography. The purified protein precipi-
tated upon dialysis into water and was collected by centrifugation. The protein
was then dissolved in 80% formic acid in a round-bottomed flask and treated
with CNBr in the dark, in a fume hood, and under argon for 24 h. The solution
was evaporated to dryness at 28°C and resuspended in 20 mM KPO4 (pH 7.4)
and 100 mM NaCl overnight. The resulting supernatant was passed over a
high-pressure liquid chromatograph under a CH3CN-H2O gradient, and the
eluted fractions were assessed by mass spectrometry. The fraction containing
the TID25, a 49-mer peptide, contained two species: one corresponded to the
expected molecular mass of the peptide and the other was of the expected
molecular mass plus six histidines. A subsequent Ni-affinity assay also indicated
that the larger of the two peptide species still contained a C-terminal His tag.
GST pull-down assays. The transactivation-inhibitory (TI) domain (residues
566 to 641 or 569 to 616) and the TA domain (residues 1 to 26, 1 to 34, or 1 to
141) of p63 were each expressed as a fusion protein with an N-terminal GST and
a C-terminal His tag in Escherichia coli and purified by Ni-affinity and glutathi-
one-affinity chromatography. The GST fusion protein bound to glutathione
beads was incubated for an hour with different isoforms and mutants of p63 that
were expressed with an in vitro transcription-translation system (Promega) and
labeled with [35S]methionine or with a purified peptide (TID25). Unbound
protein was removed by centrifugation through a 0.65-m-pore-size filter unit
(Amicon). The beads on the filter were washed four times with 200 l of binding
buffer (100 mM NaCl, 10% glycerol, 50 mM Tris-HCl, pH 8.0) by centrifugation.
Finally, the proteins were eluted from the beads by incubation with hot SDS
sample buffer and removed from the beads by centrifugation. After PAGE (4 to
12% NuPAGE Bis-Tris), the gels were vacuum dried at 80°C for 2 h and the
amount of each protein bound to the beads was quantified with a Phosphor-
Imager (Storm 840; Molecular Dynamics). Analysis of the band intensities was
conducted with ImageQuant 1.2. Values reported are the fractions of protein
bound compared to the amount of labeled protein loaded on the beads. As a
negative control, the experiments were repeated with only GST bound to the
beads. All experiments were performed in triplicate.
RESULTS
The last 71 residues of the  C terminus of p63 contain an
inhibitory domain. To identify the inhibitory domain in the
large  C terminus and to investigate its mechanism of inhibi-
tion, we created C-terminal deletion mutants of TAp63 and
monitored their transactivation with a luciferase assay in
SAOS-2 cells. Wild-type TAp63, the largest p63 isoform con-
taining both the TA domain and the  C terminus, shows only
very little transcriptional activity in these assays. Deleting the
last 71 residues, however, restored the activity of the protein
(TAp63TID in Fig. 1A) to a level approaching that of a p53
control. This TI domain shows no homology to any known
sequence, aside from the equivalent region of p73, and is
directly C-terminal to a SAM (sterile  motif) domain that was
recently found in the  C terminus of both p63 and p73 (5, 28).
Our finding agrees with an earlier study demonstrating trans-
activation activity for a mutant p63 identified in a human
ectrodactyly-ectodermal dysplasia-clefting syndrome patient
with a frameshift mutation toward the beginning of the SAM
domain, creating an illegitimate 13-amino-acid peptide se-
quence followed by a premature stop codon after tyrosine-525
(4). Similar results have been obtained in a study with the
p63-homologous protein p73 (36).
To investigate if this TI domain is both necessary and suffi-
cient for inhibition, we have deleted the entire  C terminus
and then added the TI domain immediately following the oli-
gomerization domain (TAp63QPSAM). This transcript,
which lacks the SAM domain as well as a glutamine- and
proline-rich domain (QP domain, also known as TAD2), shows
very low activity in our transactivation assays (Fig. 1A). In
contrast, a deletion mutant lacking the  C terminus entirely
(TAp63) is as active as TAp63. To test the possibility that
the inactivity of TAp63 and TAp63QPSAM is due to low
protein expression or rapid degradation, we examined the pro-
tein levels by Western blot analysis (Fig. 1B). Interestingly, the
inactive forms, TAp63 and TAp63QPSAM, are well ex-
pressed while the active isoforms, TAp63, TAp63TID, and
TAp63, are barely detectable, indicating that the differences
in activity cannot simply be explained by differences in protein
levels. Our result is in accordance with findings that transacti-
vating p63 isoforms have a much higher turnover rate than do
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inactive isoforms (34). Overall, the data presented in Fig. 1
suggest that the TI domain is both necessary and sufficient for
inhibiting the activity of p63.
The TI domain does not inhibit nuclear localization. In
agreement with results from other laboratories (5), our nuclear
magnetic resonance investigation of the TI domain has shown
that the TI domain lacks secondary structure, as characterized
by a narrow range of proton chemical shifts. Unstructured
sequences often contain signal peptides that target a protein to
a certain cellular compartment. One possible mechanism by
which the TI domain could inhibit the transcriptional activity
of p63 is by sequestering it in the cytoplasm. To investigate if
the TI domain prevents p63 from entering the nucleus, we have
carried out immunofluorescence assays by expressing TAp63
in BHK cells. The results, shown in Fig. 2, demonstrate that
TAp63 is nuclear, suggesting that the TI domain does not
influence the subcellular localization of p63. We obtained sim-
ilar results by fluorescence microscopy with cyan fluorescent
protein-TAp63 fusion proteins in COS cells (data not shown).
The TI domain of p63 binds to the N-terminal TA domain.
Several transcription factors contain domains that control their
transactivation through an intramolecular mechanism (11,
12), mainly by inhibiting DNA binding activity. To investi-
gate whether the TI domain inhibits the activity of p63 through
an intramolecular mechanism, we bacterially expressed and
purified a GST and TI domain fusion protein and conducted
pull-down experiments on several different p63 isoforms 35S
labeled in an in vitro transcription-translation system. While
TAp63 interacted with the GST-bound TI domain, Np63
did not (Fig. 3A), strongly suggesting that the TI domain in p63
binds to a region of the N-terminal TA domain. To further
test this hypothesis, we conducted pull-down experiments with
TAp63, which contains both a TA and a TI domain. An
intramolecular interaction between the two domains, as it
might occur in TAp63, should be more favorable than an
intermolecular interaction with the external GST-fused TI do-
main. Indeed, in the pull-down experiment TAp63 bound
very poorly. In accordance with this model, removal of the TI
domain from TAp63 restored binding to a level comparable
to that for TAp63, while a p63 form with the QP and the SAM
domain removed (TAp63QPSAM) also failed to bind
(Fig. 3A). Comparison of the relative transactivation (Fig. 1A)
with the results of these GST pull-down assays reveals a
strong correlation that suggests that transactivation inhibition
is linked to binding between the TI and TA domains.
The TA region of p63, while poorly conserved overall with
the TA of p53, contains a sequence that is homologous to the
MDM2 binding site (23, 31). In particular, the three hydro-
FIG. 1. The last 71 residues of the  C terminus of p63 contain an inhibitory domain. (A) The relative transactivation levels of different p63
isoforms and deletion mutants were compared with those of the wild type and a DNA-binding-incompetent mutant of p53, as described in
Materials and Methods. All values are scaled relative to the transactivation of wild-type p53, which was set to 100%. On the left the domain
structure of the individual transcripts is indicated: TA (transactivation domain), DBD (DNA-binding domain), OD (oligomerization domain), QP
(glutamine- and proline-rich domain), SAM (sterile alpha motif domain), TI (transactivation-inhibitory domain). TAp63TID, residues 1 to 570;
TAp63, residues 1 to 397; TAp63QPSAM, residues 1 to 397 and 568 to 641. (B) The lysates of p63-transfected cells used to measure relative
transactivation (above) were resolved on an SDS–4 to 12% PAGE gradient gel, transferred to a PVDF membrane, and Western blotted with
c-Myc-specific antibody 9E10. The bands that appear correspond to the expected molecular weights. The three species with high transactivation
potential, TAp63, TAp63TID, and TAp63, are not visible, while the inactive species, TAp63 and TAp63QPSAM, are abundant.
Numbers at right are molecular weights in thousands.
FIG. 2. The TI domain does not inhibit nuclear localization. Im-
munofluorescence was used to examine the cellular localization of
TAp63, as described in Materials and Methods. myc-tagged TAp63
was stained with the c-Myc-specific antibody 9E10 (left). The DNA was
visualized with the fluorochrome Hoechst 33278 (right). The nuclear
staining of TAp63 reveals that the TI domain does not inhibit nuclear
localization of the p63 transcription factor.
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phobic residues, F16, W20, and L23, which are deeply buried
in a cleft in MDM2 in its complex with p53 (23), are conserved
in p63 and p73 (Fig. 4). An interaction between MDM2 and
the p73 protein has been reported in the literature, though,
surprisingly, the interaction does not lead to degradation of
p73 but inhibition of its transactivation potential (2, 8, 33, 48,
52). In the case of p63, several conflicting reports have been
published. While some research groups do not find interaction
between MDM2 and p63, others suggest that an interaction
occurs that can either suppress transcriptional activity or en-
hance it (3, 19, 21, 25, 48). The sequence contacted by MDM2
has been shown elsewhere for p53 to be important for trans-
activation by binding to the TATA binding protein (14) as
well as to several TATA binding protein-associated factors
(TAFII40 and TAFII60) (26, 45). These observations, together
with our finding that the TI domain binds the TA domain,
suggest a mechanism by which the TI domain binds to the
equivalent cofactor recruitment site in p63 and, by masking it,
inhibits transactivation. As an initial test of this model, we
have created N-terminal truncation mutants that deleted the
first 13, 15, 17, 20, or 23 amino acids from the TA domain of
TAp63TID. In our TI domain interaction assay, the 13
mutant bound to the GST-TID fusion protein with an affinity
comparable to that for p63 forms with the full-length TA
domain (Fig. 3B). The 15 form bound with reduced affinity,
and 17, which lacks F16, the first of the three putative key
hydrophobic residues, does not bind. Further truncations, 20
and 23, also do not bind. These results suggest that the TI
domain binds to the MDM2 binding sequence in the N-termi-
nal acidic TA domain of p63 and inhibits activity by masking
important residues that presumably contact the RNA tran-
scriptional machinery.
To determine whether this conserved TA region is sufficient
for association with the TI domain, we created three GST
fusion proteins with either the first 26, first 34, or first 141
amino acids of the TA region of p63. All three fusions con-
FIG. 3. The TI domain of p63 binds to the N-terminal TA domain. (A) GST-TID pull-down assay conducted on different p63 isoforms and
deletion mutants. The gray bars show the percentages of protein bound to beads loaded with a GST-TID fusion protein, and the black bars show
the amounts of protein bound to beads loaded with equal amounts of GST alone. On the right are representative bands corresponding to the levels
of 35S-labeled protein bound to GST-TID, prior to quantification. Only p63 constructs with a free TA domain bind to the GST-TID. (B) GST-TID
pull-downs of N-terminally truncated mutants of TAp63TID. Removal of the first 15 amino acids results in a dramatic loss of binding, while
removal of 17 or more amino acids destroys binding completely. The arrow indicates the approximate location of the truncations. (C) GST fusions
to the first 26, 34, or 141 amino acids of TAp63 were used to assess binding to either Np63 (dark gray) or Np63 (light gray). GST alone bound
to neither well, while GST-26 and GST-34 did not bind to Np63 and bound with moderate affinity to Np63. GST-141 also failed to bind
Np63 but bound with high affinity to Np63. Thus, the first 34 residues are necessary for binding, but the affinity is greater upon inclusion of
additional amino acids in the TA domain.
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tained the conserved F, W, and L and were used to pull down
either Np63 or Np63 (Fig. 3C). In accordance with our
model of a TA-TI interaction, none of the GST fusions bound
to the  form of Np63 and all bound the  form. However,
GST fused to the first 141 residues of TAp63 bound to Np63
better than did either of the two shorter fusions, suggesting
that the MDM2 interaction site identified through homology
with p53 is necessary for association but that binding improves
when sequences outside the MDM2 interaction site are in-
cluded.
The conserved hydrophobic residues within the TA domain
are important both for binding the TI domain and for trans-
activation. To address the role of the three putative key hy-
drophobic side chains, F16, W20, and L23 (Fig. 5A), in binding
the TI domain, we replaced each individually with alanine in
TAp63 and performed pull-down assays with the GST-TI
domain fusion protein. These experiments demonstrated only
a slight reduction in binding affinity for all three single mutants
relative to that for wild-type TAp63 (Fig. 5B). We also tested
the transcriptional activity of all three mutants to examine
whether binding and activity are correlated as in the previous
domain deletion experiments (Fig. 1A and 3A), and we found
that the activity of the single mutants, like the binding affinity,
was basically unchanged (Fig. 5C). Mutating all three residues
simultaneously to alanine, however, had a significant effect on
binding as well as on transactivation, reducing both by about
70%. Western blots show a slight accumulation of the single
mutants and a very large buildup of the triple mutant, whereas
the wild-type protein is barely detectable (Fig. 5C). Based on
these results, a much weaker interaction between the triply
mutated TA domain and the TI domain in TAp63 is ex-
pected. A weaker intramolecular interaction within TAp63
should result in stronger binding to an external, unmutated TA
domain. Indeed, in a GST pull-down assay with the first 141
amino acids of the TA domain (GST-141), the triply mutated
TAp63 showed strong binding while wild-type TAp63 did
not bind (Fig. 5D). This triply mutated TAp63 is also com-
pletely inactive in the transactivation assay (data not shown).
Thus, the same hydrophobic side chains involved in promoting
the transactivation of p63 in the absence of a TI domain are
also involved in the stability of the protein and in binding the
TI domain.
Mutating hydrophobic residues to aspartic acid instead of
alanine can have more dramatic effects since burying a charged
side chain in a hydrophobic environment is energetically highly
unfavorable. Figure 5E shows that mutating F16 and W20 to
aspartic acid reduces the affinity by almost 50% while mutating
L23 again does not affect the binding. As expected, mutating
V15 and H18, two residues that are located on the opposite
face of the putative binding helix (Fig. 5A), does not affect the
binding affinity either. All mutation data combined suggest that
F16 and W20 are important amino acids that contribute to
binding of the TI domain, while L23 as well as amino acids on
the opposite face of the helix (V15 and H18) is not involved.
The weak effect of mutating either F16 or W20 alone to ala-
nine, however, also suggests that other regions within the first
141 amino acids of TAp63 may be involved in binding, in
agreement with our previous findings (Fig. 3C).
The TI domain is a specific inhibitor of the p63 TA domain.
Given the conservation of these three hydrophobic residues
and their importance in the association with the TI domain, we
created chimeric proteins to test whether the TI domain might
also act on p53. We began by adding the TI domain to the C
terminus of the oligomerization domain of p53 (after removing
p53’s own 26-amino-acid C-terminal regulatory domain). In
transactivation assays this chimeric protein (p53TID) showed a
50% reduction of activity relative to that of p5326 (Fig.
6A). We tested if this partial inhibition is due to binding of the
TI domain to the p53 MDM2 binding domain by GST pull-
down assays. These experiments showed no binding of p53
above that of the GST control (Fig. 6B), suggesting that the
interaction between the p63 TI domain and the p53 TA do-
main is weak at best. In contrast, a chimeric protein in which
the TA domain of p53 has been replaced with p63’s TA do-
main (TAp63p5326) is readily pulled down by the GST-TID
(Fig. 6B) and is highly active in the dual-luciferase transacti-
FIG. 4. The alignment of the amino termini of p53, TAp63, and TAp73 is shown above the domain structure model. The alignment of TI
domains of p63 and p73 is shown below. The three conserved residues important for p53 binding to MDM2 and transcriptional cofactors are
highlighted as white on dark gray. Asterisks indicate p53 residues shown to be phosphorylated under certain conditions. The SUMO-1-modified
lysine is highlighted as white on dark gray. Triangles indicate truncation points at the N and C termini used in assays depicted in Fig. 3 and 6.
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vation assays (Fig. 6A). The double chimera of p53 with the
TA domain of p63 and the TI domain of p63 (TAp63p53TID),
however, binds to GST-TID only weakly (Fig. 6B) and is se-
verely repressed in transactivation assays (Fig. 6A), simi-
lar to TAp63. When Western blot analyses are performed,
all the chimeras are undetectable with the exception of
TAp63p53TID, which is barely visible after long exposures
(data not shown). These activity and binding results suggest
that the TI domain of p63 preferentially interacts with the TA
domain of p63, even if both are presented in the context of a
different protein. The TA domain of p53, however, does not
appear to interact with the inhibitory domain.
The TI domain contains two subdomains that inhibit tran-
scription through different mechanisms. The modest reduc-
tion of transactivation of the p53TID chimera, in spite of the
absence of a detectable interaction between the TI domain and
p53, prompted us to look into alternative mechanisms of trans-
activation repression. Since it remains possible that a weak
association between p53 and the TI domain is sufficient to
account for the loss of activity, we looked for a correlation
between disruption of the intramolecular TA-TI domain inter-
action and relief of inhibition through a series of C-terminal
truncations of TAp63. Removal of 8, 16, or 25 amino acids all
led to a small increase in transcriptional activity relative to
TAp63. Further removal of amino acids (35 and 45) re-
stored the transactivation to levels comparable to those for
TAp63TID. Western blot analysis of these transactivation
assays showed high protein levels for TAp63 and the 8, 16,
and 25 deletion mutants, while 35, 45, and TID are
hardly detectable (Fig. 6C), reconfirming the inverse correla-
tion of protein level with transcriptional activity observed ear-
lier (Fig. 1).
To investigate the molecular mechanism by which the relief
of inhibition occurs in these C-terminal truncations, we per-
FIG. 5. Conserved residues F16 and W20 are important both for binding to the TI domain and for transactivation. (A) A model of the putative
MDM2 binding helix within the TA domain of p63. Hydrophobic residues on one face of the helix thought to be involved in binding to
transcriptional cofactors are colored green. A pair of residues on the opposite face are colored blue. The structure is adapted from the crystal
structure of MDM2 bound to a peptide from the TA domain of p53 (23). (B) GST pull-down assays on TAp63 containing TA domain mutations
to alanine. The gray bar shows the percentage of wild-type TAp63 bound to beads loaded with a GST-TID fusion protein, the green bars show
the percentages of bound mutant TAp63, and the black bars show the amounts of TAp63, wild type or mutant, bound to beads loaded with GST
only. (C) The relative transactivation levels of wild-type TAp63 and TA domain mutants were compared. All values are scaled relative to the
transactivation of wild-type TAp63, which was set to 100% and appears gray. The transactivation levels of the mutants are shown in green. The
lysates of transfected cells used to measure relative transactivation were resolved and Western blotted with the anti-p63 4A4 antibody. The bands
are of the same size and correspond to the expected molecular weight. (D) GST pull-down assays on TAp63 containing a triple mutation in the
TA domain. The gray bar shows the percentage of wild-type TAp63 bound to beads loaded with GST fused to the first 141 amino acids of the TA
domain, while the green bar indicates the percentage of TAp63 with F16A, W20A, and L23A mutations bound. The black bars show the amounts
of protein bound to beads loaded with GST only. (E) GST pull-down assays on TAp63 containing TA domain mutations to aspartate. The gray
bar shows the percentage of wild-type TAp63 bound to beads loaded with a GST-TID fusion protein, the green and blue bars show the per-
centages of mutant TAp63 bound, and the black bars show the amounts of protein bound to beads loaded with GST only.
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FIG. 6. The TI domain is a specific inhibitor of the p63 TA domain. (A) Relative transactivation of different chimeras composed of swapped
domains of p63 and p53. p5326, residues 1 to 361 of p53; p53TID, residues 1 to 361 of p53 and 568 to 641 of p63; TAp63p5326, residues 1 to
127 of p63 and 92 to 361 of p53; TAp63p53TID, residues 1 to 127 of p63, 92 to 361 of p53, and 568 to 641 of p63. Shaded segments represent p53
domains, and nonshaded segments represent p63 domains. (B) GST pull-down assay on different p53/p63 chimeras. The gray bars show the
percentages of protein bound to beads loaded with a GST-TID fusion protein, and the black bars show the amounts of protein bound to beads
loaded with GST only. (C) The relative transactivation levels of TAp63 with various C-terminal truncations were compared with that for a
DNA-binding-incompetent mutant of p53. All values are scaled relative to the transactivation of TAp63TID, which was set to 100%. TAp63
mutants lacking the last 8 (8), 16 (16), or 25 (25) amino acids show a moderate increase in activity relative to full-length TAp63. 35, 45,
and TID (missing the last 71 residues) have high activity. The arrow indicates the approximate location of the truncations. The lysates of
transfected cells used to measure relative transactivation were resolved on an SDS–4 to 12% PAGE gradient gel, transferred to a PVDF
membrane, and Western blotted with the anti-p63 4A4 antibody. The bands correspond to the expected molecular weights, gradually decreasing
from left to right. (D) Results of GST-TID pull-down assays with C-terminally truncated forms of TAp63. GST-TID fails to bind TAp63
presumably because the intramolecular association is more favorable than the same association in trans. Removal of the last 35 or more residues
leads to a sudden and dramatic improvement in binding most likely caused by a disruption of the intramolecular TI-TA domain interaction.
(E) GST pull-down assay with a truncated TI domain. The affinities of different p63 isoforms for a truncated form of the TI domain lacking the
last 25 amino acids (GST-TID25) were measured. The results are very similar to the results obtained with GST fused to the full-length TI domain.
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formed pull-down assays (Fig. 6D). The 8, 16, and 25
deletion mutants did not show any increase in binding affinity
to the GST-TID fusion protein relative to TAp63. Such an
increase in binding would be expected if the C-terminal trun-
cation disrupted the native intramolecular TA-TI domain in-
teraction, allowing the GST-TID to bind in trans. Removal
of 35 or more amino acids from the C terminus, however,
restored binding affinity to levels comparable to those for
TAp63TID. These results clearly demonstrate that the last
25 amino acids in the TI domain of p63 are unnecessary for
binding to the TA domain. We confirmed these results by
performing pull-down assays with the 25 truncation mutant of
the TI domain fused to GST (GST-TID25). This construct
was able to bind TAp63 and TAp63TID, but not Np63
or TAp63, with relative affinities that are indistinguishable
from those for GST fused to the full-length TI domain (Fig.
6E). Thus, short C-terminal deletions (8, 16, and 25) par-
tially relieve inhibition, though the intramolecular TA-TI do-
main interaction remains intact, implying that the TI domain
may contain two subdomains with different inhibitory mecha-
nisms. This interpretation is further supported by our Western
blot analysis of the protein levels in the transactivation assays.
In agreement with our earlier results (Fig. 1), all p63 forms that
are inactive due to binding of the TI domain to the TA domain
accumulate in the cell and can be detected as strong bands in
Western blots. In contrast, all active p63 forms in which the TA
domain is not masked by the TI domain are barely detectable,
most likely due to rapid turnover of the protein. Further sup-
port for our model of two different subdomains within the TI
domain is based on sequence comparison between p63 and
p73. The sequence of p73 that shows high homology to the TI
domain of p63 has a polyglycine insertion 25 amino acids from
the C terminus (Fig. 4). This insertion coincides with the po-
sition beyond which further removal of amino acids eliminates
the TA-TI domain interaction and may mark a boundary be-
tween these inhibitory subdomains.
The last 25 amino acids, on the other hand, seem to inhibit
the activity of p63 by an additional mechanism that is different
from the binding of the TI domain to the TA domain. Inter-
estingly, the last eight amino acids in p63 contain a conserved
lysine that becomes covalently modified by the ubiquitin ho-
mologue SUMO-1 in p73 (30) (Fig. 4). Covalent attachment of
ubiquitin or SUMO-1 has been shown elsewhere to affect pro-
tein stability and can affect their turnover rate inside cells (6).
Sumoylation might, therefore, explain the inhibitory effect of
the TI domain on p53 as well as the partial relief of inhibition
by the 8, 16, and 25 mutants. Since the activities of the 8,
16, and 25 truncation mutants are relatively similar, this
additional inhibitory effect is most likely localized in the last
eight amino acids. If this model is correct, removing the last
eight amino acids from the C terminus of the TI domain in the
p53TID chimera should relieve the partial inhibition with this
chimera that we observed as shown in Fig. 6A. Indeed, in
transactivation assays the p53TID8 construct showed a tran-
scriptional activity that is indistinguishable from that of wild-
type p53.
Thus, the combination of the results of the pull-down assays,
transactivation assays, Western blot analysis, and sequence
comparison strongly suggests that the first 50 residues of the
TI domain inhibit transactivation by binding to the TA domain,
while the last 25 residues may be involved in associations with
other proteins that modulate stability and activity of p63. In-
terestingly, a human patient with split-hand–split-foot malfor-
mation caused by a nonsense mutation at Q634 has been iden-
tified elsewhere (47). This mutation creates a form of p63
that lacks the last eight amino acids (8 form) and demon-
strates, in accordance with our results, the importance of even
just the last eight amino acids for p63’s biological function.
To investigate the exact mechanism by which binding of the
TI domain to the TA domain inhibits transcriptional activity,
we investigated the interaction of the first 141 amino acids of
the TA domain with several cofactors of the transcriptional
machinery (TAFII32, TAFII40, TAFII60, TAFII70, TAFII250,
CBP, and p300) both by pull-down assays with GST-141 and by
immunoprecipitation. None of these factors bound signifi-
cantly above background levels, suggesting either that different
cofactors are involved in p63 transcriptional activity or that
posttranslational modifications, in particular phosphorylation,
might be necessary to establish an interaction.
The TI domain binds directly to the TA domain. The pull-
down experiments described so far were performed in rabbit
reticulocyte lysates as part of the in vitro transcription-trans-
lation kit used to label the p63 isoforms with 35S. To explore
the possibility that there might be a rabbit protein in the lysates
that mediates the TA-TI domain association, we conducted
pull-downs exclusively with purified proteins made recombi-
nantly in E. coli. The GST-TA fusions were used to assess
binding to the first 49 residues of the TI domain (TID25), and
the results were assessed by Coomassie blue staining (Fig. 7).
In agreement with our results shown in Fig. 3C, the GST alone
did not bind the TI peptide, but fusions of the GST to TA
peptides of increasing length did. Once again, the GST fused
to the first 141 residues bound better than did GST fused to the
first 26 or 34 residues. This experiment demonstrates that the
TA-TI domain interaction is indeed direct and also suggests
that no posttranslational modification is required for either
domain to drive the association.
DISCUSSION
Our experiments demonstrate that p63 and p53 employ dif-
ferent mechanisms to regulate transcriptional activity. p53 also
contains a regulatory domain at its extreme C terminus which
is, in contrast to the TI domain of p63, only 26 amino acids
long. More importantly, the mechanism of inhibition seems to
be different, as the inhibitory domain of p53 is involved in
regulating the sequence-specific binding affinity of the DNA-
binding domain (15, 16, 24) while the TI domain of p63 binds
to the N-terminal TA domain. The closely related protein p73
shows a very similar domain structure, including a TI domain
and a SAM domain in its  C terminus. This high sequence
homology between the two proteins (Fig. 4) predicts that the
results shown here are relevant not only for p63 but also for
p73.
Np63 and Np63 display a similar and moderate dom-
inant-negative effect toward p53 but radically different effects
toward transactivating TAp63 (49). TAp63 is, if at all, only
weakly repressed by Np63 but very strongly repressed by
Np63, the major p63 isoform in cells. In light of our results,
these different effects of p63 isoforms on p53 and TAp63 can
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now be interpreted. The TI domain of Np63 cannot interact
intramolecularly since it lacks its own TA domain. However,
p63 tetramerizes (7), and formation of hetero-oligomers be-
tween TAp63 and Np63 could allow the TI domain to
interact with the TA domain of another protein within the
tetramer. A 2:2 complex of Np63 and TAp63 would, there-
fore, reduce the number of active TA domains in the tetramer
to zero (Fig. 8A), powerfully inhibiting the activity of TAp63.
Np63, however, lacks the TI domain, and a 2:2 complex with
TAp63 will leave two active TA domains (Fig. 8B). Thus, by
controlling the ratios of the different isoforms through alter-
native splicing, the activity of p63 may be fine-tuned.
With respect to p53, Np63 and Np63 show very similar
levels of inhibition. Earlier results have suggested that p53 and
p63 cannot form hetero-oligomers (7), and the inhibitory ef-
fects of Np63 isoforms on p53 were attributed to competition
for DNA-binding sites (49). Other research laboratories have
reported a direct interaction between p53 and p63 in their
DNA-binding domains (38). In addition, Pozniak et al. have
shown that N isoforms of p73 play an antiapoptotic role and
are direct antagonists of p53 in sympathetic neurons (37). They
attribute this antagonistic role of p73 to direct binding to p53.
While our results suggest that the TI domain of p63 cannot
directly bind to the TA domain of p53 and inhibit its transac-
tivation potential, they are consistent with a model based on
competition for DNA-binding sites and do not contradict a
possible association through the DNA-binding domains. The
combined results of all research groups are also consistent with
a model in which p63 and p73 are involved in regulatory net-
works with p53 and control p53’s apoptotic function in neurons
and epithelial stem cells. Most likely, however, the TI domain
is used only for the direct regulation of the transcriptional
control of p63 and maybe p73, but not in interactions with p53.
Our results explain why TAp63 shows a low level of trans-
activation relative to that of TAp63 and explain the strong
dominant-negative effect of Np63 on transactivating p63
isoforms. Based on our data, it is now possible to integrate a
wealth of other studies about p63 regulation into one consis-
tent model. In this model, a high concentration of Np63
immediately inactivates any small concentration of active p63
isoforms and keeps them in an inhibited complex. Complex
formation of active p63 isoforms with Np63 increases the
lifetime of the TA domain-containing forms while keeping
them in an inactive state. To activate the transcriptional po-
tential of p63, only the inhibitory interaction between the TI
and the TA domains has to be relieved, thereby avoiding time-
consuming protein expression. In this way, differential splicing
of the p63 gene can create a transcriptional regulatory complex
that allows the cell to control the activity of p63 in a fast,
switch-like manner.
Several lines of evidence support such a model. First,
Np63 is the most abundant isoform found in epithelial cells,
and it has been demonstrated that even a mutant Np63
FIG. 7. The TI domain binds directly to the TA domain. The
GST-TA fusions used in Fig. 3C were used to assess binding to a
recombinantly expressed and purified TID25 peptide (residues 568 to
616). Lane 1 contains the purified TID25 peptide. The doublet is due
to the presence (higher molecular weight) or absence (lower molecular
weight) of a C-terminal six-histidine tag as indicated by both mass
spectrometry and nickel affinity (see Materials and Methods). The
histidine tag does not appear to affect the affinity of the TID25
peptide for the TA domain. The peptide was incubated with either
GST, GST-26, GST-34, or GST-141 fusion proteins bound to glutathi-
one-Sepharose, washed, eluted with hot SDS sample buffer, and run in
lanes 2, 3, 4, and 5, respectively. The very high molecular weight bands
correspond to the GST fusions and occur at roughly equivalent con-
centrations. The low-molecular-weight doublet indicates the fraction
of TID25 still bound to the fusions following the washes. GST alone
does not bind a detectable amount of peptide, while GST-26 and
GST-34 bind with moderate affinity and GST-141 binds with high
affinity. Numbers at left are molecular weights in thousands.
FIG. 8. Models of p63 heterotetramers. (A) In a tetramer consist-
ing of two TAp63 (green) and two Np63 (red) monomers, the TI
domains of Np63 can interact with and inhibit both TA domains of
the TAp63 monomers. Activation of this tetramer could occur by
recruiting another protein, e.g., a kinase that disrupts the TI-TA do-
main interaction. Binding of kinase or the other factor, illustrated as
“X,” could be facilitated by the SAM domain. (B) Tetramerization of
two TAp63 monomers (green) with two Np63 monomers (yellow)
leaves both TA domains active.
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incapable of binding DNA retains the strong dominant-nega-
tive effect toward active p63 isoforms, while losing its domi-
nant-negative effect on p53. This suggests that the inhibition of
active p63 isoforms by Np63 is not due to competition for
DNA-binding sites but occurs through direct interaction be-
tween the isoforms. Second, several reports have demonstrated
that p63 isoforms with an active TA domain are barely detect-
able by immunochemistry (40, 49), and the TA domain has
been implicated in the responsibility for fast degradation (34).
In contrast, Np63 isoforms, which lack the TA domain, seem
to be more stable. Further supporting these observations, mu-
tations made in the putative MDM2 binding helix of p63 dra-
matically increase stability of the protein (Fig. 5C), and notably
these same residues are involved in an association with the TI
domain (Fig. 3B and C, 5B, and 7). Thus, when sites within the
TA domain responsible for fast degradation are masked by the
TI domain, protein stability and protein levels should increase,
and indeed, our results indicate that TA isoforms containing
the TI domain accumulate to significantly higher levels than
those without (Fig. 1B and 6C). According to our model, this
masking and stabilization could also occur in trans in hetero-
oligomeric complexes containing Np63 and TAp63/. Fi-
nally, the central, biological role that the  C terminus plays in
p63 is emphasized by the analysis of p63 mutations in human
patients. Surprisingly, patients with mutations in the  C ter-
minus that partially abolish the inhibitory function of the TI
domain and create transcriptionally active p63 forms show
very similar phenotypes as do patients with mutations in the
DNA-binding domain that abolish DNA binding of all p63
isoforms (4). While the mechanism of how loss of inhibition in
the  isoforms and loss of DNA binding in all isoforms lead to
similar phenotypes is currently unknown, it shows that the
inhibitory function in the TI domain is of paramount impor-
tance.
The question remains how p63 becomes active. Our results
indicate that disruption of the inhibitory interaction between
the TI and the TA domains would trigger p63’s transactivation
potential. Such a trigger could be phosphorylation of either of
the two domains, and several known sites of phosphorylation in
the TA domain of p53 are conserved in p63 (Fig. 4). As dis-
cussed above, potential regulatory sites for the TA-TI interac-
tion might be located in the last 25 amino acids of the TI
domain. Alternatively, since SAM domains are protein-protein
interaction modules that are found in a large variety of differ-
ent protein classes, the SAM domain that is located directly
N-terminal to the TI domain could recruit, for example, ki-
nases (Fig. 8). A recent analysis of mutations found in the
SAM domain of p63 in human patients (28) has suggested a
binding site for a potential interaction partner that is different
from the SAM-SAM domain dimerization interface found in
several SAM domain structures so far (41, 42, 44). This opens
the possibility that the p63 SAM domain might interact with a
binding partner that is not another SAM domain. Studies to
address these questions are being carried out.
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